Literature DB >> 27404867

Stemcentrx bags $5.8 billion, even as Notch agent underwhelms.

Eva von Schaper.   

Abstract

Year:  2016        PMID： 27404867     DOI： 10.1038/nbt0716-683a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Authors:  Laura R Saunders; Alexander J Bankovich; Wade C Anderson; Monette A Aujay; Sheila Bheddah; KristenAnn Black; Radhika Desai; Paul A Escarpe; Johannes Hampl; Amy Laysang; David Liu; Javier Lopez-Molina; Milly Milton; Albert Park; Marybeth A Pysz; Hui Shao; Brian Slingerland; Michael Torgov; Samuel A Williams; Orit Foord; Philip Howard; Jacek Jassem; Andrzej Badzio; Piotr Czapiewski; David H Harpole; Afshin Dowlati; Pierre P Massion; William D Travis; M Catherine Pietanza; J T Poirier; Charles M Rudin; Robert A Stull; Scott J Dylla
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

Review 2.  Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine.

Authors:  William D Travis
Journal:  Thorac Surg Clin       Date:  2014-08       Impact factor: 1.750

3.  Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer.

Authors:  Tianyun Jiang; Brendan J Collins; Ning Jin; David N Watkins; Malcolm V Brock; William Matsui; Barry D Nelkin; Douglas W Ball
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.